Jefferies Downgrades Calliditas Therapeutics to Hold, Lowers Price Target to $39
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Maury Raycroft has downgraded Calliditas Therapeutics (NASDAQ:CALT) from Buy to Hold and lowered the price target from $58 to $39.
May 28, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Jefferies has downgraded Calliditas Therapeutics from Buy to Hold and reduced the price target from $58 to $39.
The downgrade from Buy to Hold and the significant reduction in the price target from $58 to $39 by Jefferies is likely to negatively impact investor sentiment and the short-term stock price of Calliditas Therapeutics.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100